Hospira’s Sodium Chloride Ripe for ANDAs: FDA
Federal Register notice: FDA has determined that Hospira’s sodium chloride 14.6% solution for injection (50 milliequivalent/20 milliliters) in plastic containers was not withdrawn due to safety or effectiveness reasons. The determination will allow FDA to approve ANDAs that reference the product if all other legal and regulatory requirements are met. To view the notice, click here.